Alaunos Therapeutics (TCRT) Equity Ratio (2009 - 2026)

Alaunos Therapeutics has reported Equity Ratio for 18 years, with the latest figure at 0.68 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio rose 37.06% year-over-year to 0.68; the trailing twelve-month figure through Mar 2026 stood at 0.68 (up 37.06% YoY), and the FY2025 full-year result was 0.74, down 0.95% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.68, down from 0.74 in the prior quarter.
• The five-year high for Equity Ratio was 0.81 in Q2 2024, with the low at 0.48 in Q3 2022.
• Historically, Equity Ratio has averaged 0.68 across 5 years, with a median of 0.74 in 2025.
• Annual changes were most pronounced in 2023 — Equity Ratio soared 49.95% — and 2025, when it tumbled 37.21%.
• Alaunos Therapeutics' Equity Ratio stood at 0.59 in 2022, then climbed by 28.56% to 0.76 in 2023, then fell by 1.89% to 0.75 in 2024, then declined by 0.95% to 0.74 in 2025, then decreased by 7.78% to 0.68 in 2026.
• The last three Equity Ratio figures came in at 0.68 (Q1 2026), 0.74 (Q4 2025), and 0.75 (Q3 2025), per Business Quant data.